Mast cells (MCs) are involved in several biological processes, such as defense against pathogens, immunomodulation, tissue repair after injury, and angiogenesis. MCs have been shown to change from protective immune cells to potent pro-inflammatory cells, influencing the progression of many pathological conditions, including autoimmune diseases and cancers. The role of MCs in the pathogenesis of rhinopathies has often been underestimated, since previous studies have focused their attention on eosinophils and neutrophils, while MCs were considered involved exclusively in allergic rhinitis. However, recent nasal cytology findings have shown the involvement of MCs in several rhinopathies, such as NARMA, NARESMA, and CRSwNP. These recent evidences highlight the crucial role that MCs play in orchestrating the inflammation of the nasal mucosa, through complex biological mechanisms, not yet fully understood. In this context, a better understanding of these mechanisms is fundamental for practicing Precision Medicine, which requires careful population selection and stratification into subgroups based on the phenotype/endotype of the patients, in order to guarantee the patient a tailored therapy. Based on this background, further studies are needed to understand the pathophysiological mechanisms involving MCs and, consequently, to develop targeted therapies aimed to obtain a selective inhibition of tissue remodeling and preventing MC-mediated immune suppression.
Int Arch Allergy Immunol

中文翻译：

---

肥大细胞在鼻病发病机制中的作用被低估

肥大细胞 (MC) 参与多种生物学过程，例如防御病原体、免疫调节、损伤后的组织修复和血管生成。已显示 MC 从保护性免疫细胞转变为有效的促炎细胞，影响许多病理状况的进展，包括自身免疫性疾病和癌症。MCs 在鼻病发病机制中的作用经常被低估，因为以前的研究将注意力集中在嗜酸性粒细胞和中性粒细胞上，而 MCs 被认为只与过敏性鼻炎有关。然而，最近的鼻细胞学研究结果表明 MC 参与了几种鼻病，例如 NARMA、NARESMA 和 CRSwNP。这些最近的证据强调了 MC 在协调鼻粘膜炎症中所起的关键作用，通过复杂的生物学机制，尚未完全了解。在这种情况下，更好地理解这些机制是实施精准医学的基础，这需要根据患者的表型/内型进行仔细的人群选择和亚组分层，以确保患者获得量身定制的治疗。基于此背景，需要进一步研究以了解涉及 MCs 的病理生理机制，从而开发旨在获得选择性抑制组织重塑和预防 MC 介导的免疫抑制的靶向治疗。这需要根据患者的表型/内型进行仔细的人群选择和分组，以确保患者获得量身定制的治疗。基于此背景，需要进一步研究以了解涉及 MCs 的病理生理机制，从而开发旨在获得选择性抑制组织重塑和预防 MC 介导的免疫抑制的靶向治疗。这需要根据患者的表型/内型进行仔细的人群选择和分组，以确保患者获得量身定制的治疗。基于此背景，需要进一步研究以了解涉及 MCs 的病理生理机制，从而开发旨在获得选择性抑制组织重塑和预防 MC 介导的免疫抑制的靶向治疗。
Int Arch 过敏免疫